AIHealthcare

Orionis Biosciences is a privately held, clinical-stage biotechnology company developing precision therapeutics for life-threatening diseases, with a primary focus on oncology and immunotherapy. Its proprietary technology includes the Allo-Glue platform and an AI-driven drug-discovery engine used to identify and design molecular-glue therapeutics and biologics for challenging targets. The company operates a transatlantic research organization with headquarters in Waltham, Massachusetts, and a research facility in Ghent, Belgium. Its market position is that of an emerging molecular-glue drug-discovery and development specialist, supported by collaborations and financing from major pharmaceutical and institutional investors; however, it is not a publicly traded company and no independently verified market-share data is available.